Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

144.13 -1.52 (-1.04%)
Streaming Delayed Price Updated: 12:08 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
77 78 Next >
News headline image
Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
News headline image
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... 
Via Benzinga
News headline image
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Will GILEAD SCIENCES INC breakout? ↗
Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC. 
Via Chartmill
News headline image
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today ↗
 
Via Benzinga
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
News headline image
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
News Is Noise ↗
Via Talk Markets
News headline image
Biotech Stocks Poised For Another Big Move In Q4 ↗
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
News headline image
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion' ↗
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Gilead Sciences Unusual Options Activity For September 20 ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗
 
Via Benzinga
News headline image
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Top 4 Health Care Stocks That May Keep You Up At Night ↗
 
Via Benzinga
News headline image
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles ↗
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining... 
Via Benzinga
Topics Product Recall
News headline image
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
News headline image
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug ↗
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment. 
Via Investor's Business Daily
News headline image
3 Dirt Cheap Stocks to Buy Right Now ↗
Bargain hunters should love these great stocks. 
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Why Gilead Sciences Stock Thrashed the Market Today ↗
In drug development, solid performance in large-scale clinical trials is crucial. 
Via The Motley Fool
News headline image
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections ↗
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by... 
Via Benzinga
News headline image
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention ↗
The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs. 
Via Investor's Business Daily
Topics Intellectual Property
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>